|
|
|
| Efficacy of estrazol combined with mifepristone for treating women with endometrial cancer |
| Bishan District People's Hospital, Chongqing, 402760 |
|
|
|
|
Abstract To investigate the effect of paclitaxel combined with mifepristone for treating patients with endometrial cancer on their serum tumor markers, matrix metalloproteinase-9 (MMP-9), and vascular endothelial growth factor (VEGF) levels. Methods: 96 patients with endometrial cancer were selected and were randomly divided into two groups from January 2015 to December 2019. The patients in the control group were treated by paclitaxel, and the patients in the study group were treated by paclitaxel combined with mifepristone. The levels of serum tumor markers, VEGF, MMP-9, and inflammatory factors of the patients were compared between the two groups and between before and after treatment. Results： After treatment, the levels of carbohydrate antigen 125 (30.2±6.0 U/ ml), human epididymal secreted protein 4 (28.4±13.1 pmol/L), VEGF (237.0±30.0 ng/L), MMP-9 (281.1±85.5 ng/ml), and the inflammatory factors of the patients in the study group were significant lower than those of the patients in the control group, and the excellent and good efficacy rate of curative effect (91.7%) of the patients in the study group was significant higher than that (75.0%) of the patients in the control group (all P<0.05). Conclusion: Paclitaxel combined with mifepristone for treating patients with endometrial cancer can significantly reduce the levels of serum tumor markers and inflammatory factors, and can significantly improve the inflammatory emergency response of their body, so which has better therapeutic effect.
|
|
|
|
|
|
|
|
|
